Ketamine Shows Promise for Refractory Bipolar Depression

MedPage Today Reports Antidepressive Effects in Bipolar Depression

Ketamine produced antidepressive effects in patients with treatment-refractory bipolar depression, according to a report published by MedPage Today on September 2, 2026. "Treatment-refractory" (also called treatment-resistant) bipolar depression describes depressive episodes within bipolar disorder that have not responded adequately to standard first-line treatments such as mood stabilizers, antipsychotics, or conventional antidepressants.

The MedPage Today item, syndicated through Google News, does not specify the study's sample size, ketamine dose, route of administration, treatment duration, or the journal in which the findings appeared. Readers who want those details should consult the original report directly, since this analysis is built only from the headline and summary provided and should not be treated as a substitute for the full study.

Why Bipolar Depression Is a Harder Target Than Unipolar Depression

Ketamine's antidepressant effects in major depressive disorder are well documented in the clinical literature, but bipolar depression carries an added variable: the risk of triggering a manic or hypomanic switch. Antidepressant-class treatments, including some ketamine protocols, have historically been used with more caution in bipolar patients for this reason, which is why researchers studying refractory bipolar depression typically track manic symptoms alongside depression scores. A report showing antidepressive benefit in this population is notable precisely because bipolar depression trials for any agent are less common and more tightly monitored than trials in unipolar depression.

What This Means for Oral Ketamine Tablet Users

Most published research on ketamine and mood disorders, including the bipolar depression literature generally, has centered on intravenous (IV) infusion or intranasal esketamine (Spravato), not oral tablets. The MedPage Today summary does not state which route was used in this particular report, so readers should not assume the findings transfer directly to oral or sublingual tablet dosing.

Route matters because oral ketamine has notably lower and more variable bioavailability than IV or intranasal administration, largely due to first-pass metabolism in the liver, which converts a significant portion of an oral dose into norketamine before it reaches systemic circulation. Sublingual and buccal troches partially bypass this effect by allowing some absorption through oral mucosa, while swallowed tablets rely more heavily on gastrointestinal absorption and hepatic processing. This means a dose that produces a therapeutic effect intravenously will not produce an equivalent effect if simply converted milligram-for-milligram to an oral tablet, and clinicians who prescribe oral or sublingual ketamine typically adjust dosing schedules and frequency to account for the different pharmacokinetics.

Practical Steps for Readers Considering Oral Ketamine for Mood Symptoms

If you or someone you support has bipolar depression and is considering ketamine in any form, including oral tablets, three practical steps follow from the clinical context above, independent of the specific unpublished study details:

First, confirm the diagnosis and treatment history with a psychiatric provider before starting ketamine, since bipolar depression requires a different risk assessment than unipolar depression, particularly around mood-stabilizer coverage and manic-switch risk. Second, ask your prescriber directly which route they are using, oral tablet, sublingual troche, intranasal, or IV, and why, since the dosing rationale and expected onset differ meaningfully between them. Third, track mood symptoms in both directions during any ketamine course. Depression rating scales alone can miss an emerging hypomanic or manic episode, so structured monitoring should include both depression and mania screening tools, not depression scores alone.

What We Still Don't Know

Because the available report is a short news summary rather than the underlying study, key questions remain open: the sample size, whether the study was randomized and placebo-controlled, the specific ketamine route and dose, treatment duration, and how researchers defined and measured "refractory" for enrollment. Readers who want to evaluate the strength of this evidence should look for the peer-reviewed publication behind the MedPage Today report rather than relying on the summary alone. As with any early or single-report finding, this should be read as one data point in an evolving research picture on ketamine and bipolar depression, not a settled clinical guideline.